Alliance Global Partners initiated coverage on Quantum-Si with a new price target
$QSI
Industrial Machinery/Components
Industrials
Alliance Global Partners initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.75
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/7/2025 | $3.75 | Buy | Alliance Global Partners |
| 12/8/2023 | $3.00 | Buy | H.C. Wainwright |
| 9/25/2023 | $3.50 → $2.00 | Buy → Hold | Canaccord Genuity |
| 10/20/2021 | $13.00 | Buy | Canaccord Genuity |
Alliance Global Partners initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.75
H.C. Wainwright initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.00
Canaccord Genuity downgraded Quantum-Si from Buy to Hold and set a new price target of $2.00 from $3.50 previously
SCHEDULE 13G/A - Quantum-Si Inc (0001816431) (Subject)
SD - Quantum-Si Inc (0001816431) (Filer)
8-K - Quantum-Si Inc (0001816431) (Filer)
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, announces participation in an expert panel during the upcoming GenomeWeb-hosted webinar, "From Raw to Reusable: Considerations for Data Integration and Real-World Standardization in Proteomics." When: June 20, 2025, at 8 a.m. PDT/11 a.m. EDT This one-hour webinar will explore critical strategies for improving the accessibility, integration, and standardization of data across proteomics platforms. Attendees will learn how to deposit data into public repositories, apply metadata annotation best practices, normalize cros
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, announces a featured talk at the upcoming Festival of Genomics & Biodata Boson, highlighting innovative advances in protein sequencing technology for drug development. Melissa Deck, Director of Platform at Liberate Bio, will present "Precision Proteomics: Advancing Drug Development with Next-Gen Protein Sequencing™ (NGPS™)," showcasing how Quantum-Si's Platinum® Pro instrument is transforming the way scientists study proteins. Session Highlights Include: Introduction to single-molecule protein sequencing with NGPS™
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that the Compensation Committee of Quantum-Si's Board of Directors has granted 45,529 restricted stock units ("RSUs") to new employees under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the "2023 Inducement Plan"). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Inducement Plan is used exclusively for the grant of equity awards